Compare Oatly Group AB - ADR (OTLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Zimmer Biomet Holdings Inc — how do they compare? Oatly Group AB - ADR trades at $10.59 (market cap $330.93M), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 51.2× Oatly Group AB - ADR's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| OTLY | ZBH | |
|---|---|---|
Market Cap | $330.93M | $16.95B |
Volume | 68,708 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $103.98 |
52-Week Low | $8.03 | $79.58 |
Typical Hold Time | 18 Days | 89 Days |
Enterprise Value | $835.34M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.59, up 2.12% today, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, reflecting margin improvements. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment. However, negative cash flows and high debt-to-asset ratio of 66.53% in 2025 pose risks. Analyst consensus is mixed with a $12.28 price target, indicating modest upside potential from current levels.
Outlook: OTLY shows operational progress with revenue growth and reduced losses, but profitability remains elusive. Investment opportunity hinges on sustained margin expansion and positive EBITDA. Key risks include cash burn, competitive pressures, and leverage. Investors should weigh turnaround potential against financial stability concerns.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
